RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma

[1]  J. George,et al.  A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. , 2017, Cancer research.

[2]  A. Cañete,et al.  Advances in emerging drugs for the treatment of neuroblastoma , 2017, Expert opinion on emerging drugs.

[3]  A. Califano,et al.  HAUSP deubiquitinated and stabilizes N-Myc in neuroblastoma , 2016, Nature Medicine.

[4]  K. Matthay,et al.  Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. , 2016, European journal of cancer.

[5]  Lian Chen,et al.  Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells. , 2016, Acta biochimica et biophysica Sinica.

[6]  D. K. Lowe,et al.  Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. , 2016, The Annals of pharmacotherapy.

[7]  D. Dimitrov,et al.  A dual‐specific anti‐IGF‐1/IGF‐2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma , 2015, International journal of cancer.

[8]  S. Agarwal,et al.  The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma , 2015, Cell Death Discovery.

[9]  Zhenyu Zhu,et al.  RLIP76 Blockade by siRNA Inhibits Proliferation, Enhances Apoptosis, and Suppresses Invasion in HT29 Colon Cancer Cells , 2015, Cell Biochemistry and Biophysics.

[10]  J. Vincent,et al.  Inhibitors of endocytosis prevent Wnt/Wingless signalling by reducing the level of basal β-catenin/Armadillo , 2014, Journal of Cell Science.

[11]  Yuan Li,et al.  Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/β-catenin signaling in neuroblastoma. , 2014, Cancer letters.

[12]  Zhuogang Liu,et al.  Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells , 2014, Tumor Biology.

[13]  H. Mott,et al.  Structure and function of RLIP76 (RalBP1): an intersection point between Ras and Rho signalling. , 2014, Biochemical Society transactions.

[14]  R. Gabdoulline,et al.  ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis , 2014, Cell Death and Differentiation.

[15]  D. Nietlispach,et al.  The Structure of the RLIP76 RhoGAP-Ral Binding Domain Dyad: Fixed Position of the Domains Leads to Dual Engagement of Small G Proteins at the Membrane , 2013, Structure.

[16]  Seunghyung Lee,et al.  Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter , 2013, Lung Cancer.

[17]  William A Weiss,et al.  Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.

[18]  Zhongwei Lv,et al.  RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis. , 2013, Carcinogenesis.

[19]  M. Lodish.  Kinase Inhibitors: Adverse Effects Related to the Endocrine System , 2013 .

[20]  Juxiang Chen,et al.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells , 2013, Journal of Neuro-Oncology.

[21]  Tony T. Huang.  Deubiquitinases as a signaling target of oxidative stress , 2012, Cell reports.

[22]  S. Awasthi,et al.  RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. , 2012, Cancer research.

[23]  M. Koch,et al.  Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse , 2012, Cancer biology & therapy.

[24]  S. Awasthi,et al.  RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer , 2012, PloS one.

[25]  M. Rossner,et al.  Regulation of the EGF Transcriptional Response by Endocytic Sorting , 2012, Science Signaling.

[26]  W. Gu,et al.  p53 regulation by ubiquitin , 2011, FEBS letters.

[27]  U. Kees,et al.  MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63 , 2011, Oncogene.

[28]  R. Vatsyayan,et al.  Targeting p53-Null Neuroblastomas through RLIP76 , 2011, Cancer Prevention Research.

[29]  Sumihiro Suzuki,et al.  Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis , 2011, Molecular Cancer Therapeutics.

[30]  M. Conaway,et al.  RalBP1 is necessary for metastasis of human cancer cell lines. , 2010, Neoplasia.

[31]  M. Barton,et al.  Making sense of ubiquitin ligases that regulate p53 , 2010, Cancer biology & therapy.

[32]  R. Vatsyayan,et al.  Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling. , 2010, Biochemistry.

[33]  R. Vatsyayan,et al.  RLIP76: a versatile transporter and an emerging target for cancer therapy. , 2010, Biochemical pharmacology.

[34]  N. Cheung,et al.  Neuroblastoma: Therapeutic strategies for a clinical enigma. , 2010, Cancer treatment reviews.

[35]  M. Kubota,et al.  Mortality and morbidity of patients with neuroblastoma who survived for more than 10 years after treatment--Niigata Tumor Board Study. , 2010, Journal of pediatric surgery.

[36]  M. Lovell,et al.  Primary pancreatic neuroblastoma: an unusual tumor in infancy. , 2010, Journal of pediatric surgery.

[37]  Joana M. Xavier,et al.  The role of p53 in apoptosis. , 2010, Discovery medicine.

[38]  J. Leavitt,et al.  Incidence of pediatric Horner syndrome and the risk of neuroblastoma: A population-based study , 2010 .

[39]  R. Vatsyayan,et al.  A Central Role of RLIP76 in Regulation of Glycemic Control , 2009, Diabetes.

[40]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[41]  R. Vatsyayan,et al.  Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. , 2009, Cancer letters.

[42]  A. Sorkin,et al.  Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.

[43]  R. Vatsyayan,et al.  Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer , 2009, International journal of cancer.

[44]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[45]  Andrea C. Carrano,et al.  A conserved ubiquitination pathway determines longevity in response to diet restriction , 2009, Nature.

[46]  R. Vatsyayan,et al.  Role of RLIP76 in doxorubicin resistance in lung cancer. , 2009, International journal of oncology.

[47]  Y. Awasthi,et al.  RLIP76: a target for kidney cancer therapy. , 2009, Cancer research.

[48]  S. Awasthi,et al.  Regression of prostate cancer xenografts by RLIP76 depletion. , 2009, Biochemical pharmacology.

[49]  S. Singhal,et al.  RLIP76: A novel glutathione-conjugate and multi-drug transporter. , 2009, Biochemical pharmacology.

[50]  K. Matthay,et al.  Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. , 2008, Neoplasia.

[51]  M. Sahu,et al.  Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76 , 2008, FEBS letters.

[52]  Jesse D. Martinez,et al.  Hsf1 is required for the nuclear translocation of p53 tumor suppressor. , 2008, Neoplasia.

[53]  Sumihiro Suzuki,et al.  RLIP76 in defense of radiation poisoning. , 2008, International journal of radiation oncology, biology, physics.

[54]  Y. Awasthi,et al.  RLIP76 and Cancer , 2008, Clinical Cancer Research.

[55]  Y. Awasthi,et al.  Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death. , 2008, Free radical biology & medicine.

[56]  S. Awasthi,et al.  Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1* , 2008, Journal of Biological Chemistry.

[57]  J. Maris,et al.  Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification , 2008, Oncogene.

[58]  A. Gudkov,et al.  p53 determines multidrug sensitivity of childhood neuroblastoma. , 2007, Cancer research.

[59]  D. Theodorescu,et al.  Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). , 2007, Biochemical and biophysical research communications.

[60]  D. Theodorescu,et al.  Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer , 2007, Clinical Cancer Research.

[61]  P. Boor,et al.  Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). , 2007, Cancer research.

[62]  Y. Awasthi,et al.  Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. , 2007, International journal of oncology.

[63]  J. Shabanowitz,et al.  RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migration , 2006, The Journal of cell biology.

[64]  I. Watson,et al.  Ubiquitin and ubiquitin-like modifications of the p53 family. , 2006, Neoplasia.

[65]  R. Nusse,et al.  BMC Cell Biology BioMed Central Research article , 2006 .

[66]  Y. Awasthi,et al.  Regression of melanoma in a murine model by RLIP76 depletion. , 2006, Cancer research.

[67]  P. Dent,et al.  RLIP76 is a major determinant of radiation sensitivity. , 2005, Cancer research.

[68]  Y. Awasthi,et al.  POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. , 2005, Biochemical and biophysical research communications.

[69]  Jeffrey L. Wrana,et al.  Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling , 2005, Nature Reviews Molecular Cell Biology.

[70]  Y. Awasthi,et al.  Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. , 2004, Free radical biology & medicine.

[71]  G. Werther,et al.  Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system , 2004, Brain Research.

[72]  Y. Awasthi,et al.  Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G‐protein and tyrosine kinase signaling and drug resistance , 2003, International journal of cancer.

[73]  C. Rossé,et al.  RLIP, an Effector of the Ral GTPases, Is a Platform for Cdk1 to Phosphorylate Epsin during the Switch Off of Endocytosis in Mitosis* , 2003, Journal of Biological Chemistry.

[74]  L. Boni,et al.  Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  N. Mivechi,et al.  HSF-1 Interacts with Ral-binding Protein 1 in a Stress-responsive, Multiprotein Complex with HSP90 in Vivo * , 2003, The Journal of Biological Chemistry.

[76]  T. Triche,et al.  p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. , 2000, Medical and pediatric oncology.

[77]  J. Camonis,et al.  RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. , 2000, Journal of cell science.

[78]  Y. Awasthi,et al.  Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. , 2000, Biochemistry.

[79]  F. Berthold,et al.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. , 2000, Drugs.

[80]  Abraham Weizman,et al.  Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[81]  D. Stram,et al.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. , 1999, Journal of pediatric hematology/oncology.

[82]  L. Neckers,et al.  In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome , 1998, Oncogene.

[83]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[84]  J. Benítez,et al.  Correlation between mutations in p53 gene and protein expression in human lymphomas , 1997, American journal of hematology.

[85]  Park Sh,et al.  A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. , 1995 .

[86]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[87]  J. Camonis,et al.  Bridging Ral GTPase to Rho Pathways , 1995, The Journal of Biological Chemistry.

[88]  S. Cantor,et al.  Identification and Characterization of Ral-Binding Protein 1, a Potential Downstream Target of Ral GTPases , 2022 .

[89]  S. Srivastava,et al.  Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. , 1994, The Journal of clinical investigation.

[90]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[91]  M. White,et al.  Insulin receptors internalize by a rapid, saturable pathway requiring receptor autophosphorylation and an intact juxtamembrane region , 1991, The Journal of cell biology.

[92]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[93]  J. H. Wright.  NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED , 1910, The Journal of experimental medicine.

[94]  X. Liu,et al.  RLIP76 expression as a prognostic marker of breast cancer. , 2015, European review for medical and pharmacological sciences.

[95]  C. Der,et al.  Activation and involvement of Ral GTPases in colorectal cancer. , 2011, Cancer research.

[96]  M. Sahu,et al.  Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates. , 2009, International journal of oncology.

[97]  P. Dent,et al.  Is a Major Determinant of Radiation Sensitivity , 2005 .

[98]  L. Malerød,et al.  Clathrin-dependent endocytosis. , 2004, The Biochemical journal.

[99]  J. Hayes,et al.  The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.

[100]  R. Weinberg,et al.  A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. , 1995, Oncogene.

[101]  H. Esterbauer,et al.  Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.

[102]  Ananda S. Prasad.  Why a new hematology journal? , 1976 .